The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is one of the top cancer treatment and research centers in the country. In 2016, the National Cancer Institute elevated UMGCCC to its designation as a comprehensive cancer center — one of just less than 75 in the nation — a designation renewed in 2021. As part of the University of Maryland Medical System, we offer innovative approaches to diagnosing and treating all types of cancer, conduct cutting-edge research to bring the latest advances in cancer treatment directly to our patients, and provide cancer screening and patient education services. The UMGCCC is at the forefront of successful efforts which are driving down the impact of cancer in Maryland.
In 2016, UMGCCC became a National Cancer Institute (NCI)-Designated Comprehensive Cancer Center, a distinction shared by some 50 centers across the US.
Cancer research funding at UMGCCC has grown dramatically since 2002 — from $19.4 million to $122 million — and continues to drive scientific discovery by our cancer experts, all of whom are faculty of the UM School of Medicine.
UMGCCC is a leader in addressing cancer disparities, with research focused on improving access to care and treatment outcomes for minorities, who represent 53 percent of the patients in our clinical trials, compared to 16 percent nationally.
The Maryland Proton Treatment Center is a state-of-the-art facility that provides proton therapy, a highly advanced and precise form of radiation for adult and pediatric patients that increases the radiation dose to tumors while decreasing the dose to healthy, surrounding tissue.
UMGCCC is a national leader in developing immunotherapy approaches that train a patient’s own immune system to fight cancer. More than two dozen clinical trials utilize immunotherapy and are supported by UMGCCC’s Fannie Angelos GMP (Good Manufacturing Practice) Lab that permits cancer center investigators to genetically engineer patients’ T cells to recognize and attack their cancers.
UMGCCC was the first cancer center in the Baltimore/Washington area to offer CAR-T cell therapy for aggressive B cell lymphomas. We now offer CAR-T therapy for several types of B cell lymphoma, leukemia and myeloma. UMGCCC has the most advanced cell therapy research and production laboratory in the region which is developing the next generation of cellular therapies for blood cancers.
The GammaPod is a stereotactic breast radiation therapy system all designed specifically for breast cancer treatment. This FDA-cleared technology was invented at the University of Maryland School of Medicine and delivers partial breast radiation therapy in a targeted manner, and can significantly shorten treatment time with minimal side effects.
Galeterone, a drug invented at UMGCCC by investigators Dr. Angela Brodie and Dr. Vincent Njar, has shown significant activity against advanced prostate cancer. More recent studies are promising in laboratory models of pancreatic cancer. A clinical trial for this difficult disease is underway.
Dr. Graeme Woodworth received FDA clearance to become the first in the US to open the blood-brain barrier, which protects the brain from toxins but makes it difficult to treat brain cancer with chemotherapy. By using focused ultrasound and microbubbles, we can disrupt the barrier and inject an agent directly into a brain tumor
To read more about the Marlene and Stewart Greenebaum Comprehensive Cancer Center, visit: www.umms.org/umgccc.
Mr. Barry Stoler
Mrs. Marie G. Bowers
Mr. Jay C. Feinglass
Mr. S. Robert Ginsberg
Mrs. Sonya Z. Goodman
Mr. Michael I. Greenebaum
Mr. Richard Hoffman, Esq.
Mr. Erik D. Johnson
Mrs. Donna M. Maykrantz
Mr. Lawrence F. Maykrantz
Ms. Susan Mertes
Mr. Jonathan P. Myers
Ms. Ricka E. Neuman, CPA
Mr. Ian H. Neuman
Ms. Tswana Sewell
Mr. Alex Smith
Mr. Stuart Weitzman
Mrs. Roslyn Stoler
Ms. Paula Rome
Mrs. Edith Wolpoff-Davis